Hepatocellular Hypoxia-Induced Vascular Endothelial Growth Factor Expression and Angiogenesis in Experimental Biliary Cirrhosis by Rosmorduc, Olivier et al.
Hepatocellular Hypoxia-Induced Vascular
Endothelial Growth Factor Expression and
Angiogenesis in Experimental Biliary Cirrhosis
Olivier Rosmorduc,*† Dominique Wendum,‡
Christophe Corpechot,† Bruno Galy,§
Nicole Sebbagh,‡ James Raleigh,¶
Chantal Housset,*† and Raoul Poupon*†
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We tested the potential role of vascular endothelial
growth factor (VEGF) and of fibroblast growth fac-
tor-2 (FGF-2) in the angiogenesis associated with ex-
perimental liver fibrogenesis induced by common
bile duct ligation in Sprague-Dawley rats. In normal
rats, VEGF and FGF-2 immunoreactivities were re-
stricted to less than 3% of hepatocytes. One week after
bile duct ligation, hypoxia was demonstrated by the
immunodetection of pimonidazole adducts unevenly
distributed throughout the lobule. After 2 weeks, hyp-
oxia and VEGF expression were detected in >95% of
hepatocytes and coexisted with an increase in peri-
portal vascular endothelial cell proliferation, as as-
certained by Ki67 immunolabeling. Subsequently, at 3
weeks the density of von Willebrand-labeled vascular
section in fibrotic areas significantly increased. Semi-
quantitative reverse transcription polymerase chain
reaction showed that VEGF120 and VEGF164 tran-
scripts, that correspond to secreted isoforms, in-
creased within 2 weeks, while VEGF188 transcripts
remained unchanged. FGF-2 mainly consisting of a
22-kd isoform, according to Western blot, was iden-
tified by immunohistochemistry in 49% and 100% of
hepatocytes at 3 and 7 weeks, respectively. Our data
provide evidence that in biliary-type liver fibrogen-
esis, angiogenesis is stimulated primarily by VEGF in
response to hepatocellular hypoxia while FGF-2 likely
contributes to the maintenance of angiogenesis at
later stages. (Am J Pathol 1999, 155:1065–1073)
In their pioneering studies, Rappaport and co-workers
showed that the development of scars in the cirrhotic liver
was invariably accompanied by an intense vascular pro-
liferation. These authors suggested that tissue remodel-
ing and fibrous repair might represent the “road builder”
for collateral flow in cirrhosis1 Their observations have
been fully confirmed by others showing that in cirrhotic
tissues, the regenerative nodules are surrounded by a
dense vascular plexus.2,3 Yet, the mechanisms triggering
this intense vascular proliferative response remain to be
determined.
Vascular endothelial growth factor (VEGF) and fibro-
blast growth factor-2 (FGF-2) are the most potent angio-
genic factors identified thus far. Their role in vascular
proliferation associated with tumor growth or wound heal-
ing has been widely documented in different organs.4 In
addition, it has been demonstrated that hypoxia was the
main inducer of VEGF expression5 which, in turn, stimu-
lates local proliferation of capillaries to increase oxygen
delivery. Besides beneficial effects, this vascular re-
sponse may nevertheless also result in deleterious ef-
fects best illustrated by tumor growth and proliferative
retinopathy.6,7
We and others8,9 have recently observed an up-regu-
lation of VEGF in the cirrhotic liver of patients with or
without hepatocellular carcinoma, suggesting that this
factor might be responsible for cirrhosis-associated an-
giogenesis. Intrahepatic shunts and capillarization of si-
nusoids are well established characteristics of cirrhosis
that restrict the access of blood solutes to hepato-
cytes.10–12 In addition, a decrease in the hepatic micro-
vascular perfusion secondary to biliary obstruction in rat
has been recently shown to occur long before the onset
of cirrhosis, within 7 days following bile duct ligation
(BDL).13 Whether these vascular morphological and
functional alterations may induce chronic hypoxia in the
fibrotic liver and thereby elicit an angiogenic response is
unknown.
The aim of the present study was to investigate the role
of VEGF and FGF-2 in an experimental model of biliary
fibrosis. We next studied the role of hypoxia in triggering
VEGF expression and thereby in stimulating angiogene-
sis in this model.
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Materials and Methods
Animal Model of Cholestatic Liver Injury
Male Sprague-Dawley rats were used at a body weight of
200 to 250 g. The common bile duct was ligated as
described previously14 while normal and sham-operated
rats were used as controls. At various times after surgery
(3 days, 1, 2, 3, 4, 5, 6, and 7 weeks), rats were eutha-
nized with an overdose of ketamine (Parke-Davis, Cour-
bevoie, France). Cholestasis was monitored by serum
bilirubin level. At the time of sacrifice, arterial and mixed
venous blood samples were withdrawn for the measure-
ment of oxygen tension (PO2) and liver tissue was pro-
cessed as described below.
Histology and Immunohistochemistry
Liver samples were fixed in 10% buffered formalin, par-
affin-embedded and sectioned at 4 mm. Tissue sections
were stained with hematoxylin-phloxin-safran before
standard histology. Immunolabeling was performed us-
ing polyclonal antibodies against VEGF (a goat poly-
clonal IgG: sc-152-G and a rabbit polyclonal IgG: sc-507)
(1:100) (Santa Cruz Biotechnology, Santa Cruz, CA) and
FGF-2 (1:100) (Santa Cruz Biotechnology) and monoclo-
nal antibodies against von Willebrand factor (vWF) (1:
200) (Dako, Glostrup, Denmark). An avidin-biotin-perox-
idase technique (Vectastain ABC Kit, Vector, Burlingame,
CA) was used for VEGF, FGF-2, and vWF detection. For
vWF, immunoperoxidase was performed after microwave
antigen retrieval (750 W, 3 3 5 minutes in citrate buffer
0.01 mol/L, pH 6). Before immunostaining, endogenous
biotin was blocked using a commercial kit (Eurobio,
France) and endogenous peroxidase activity was inhib-
ited in 3% alcoholic hydrogen peroxide for 30 minutes.
Color development was achieved with 3-amino-9 ethyl
carbazole. The controls were obtained by omitting the
first antibody and were all negative. Two independent
sections of each sample were evaluated. The cells ex-
hibiting a moderate to intense signal for VEGF and FGF-2
were considered as positive and counted. At least 400
hepatocytes were analyzed in two independent fields.
Cell proliferation was assessed by means of a three-step
immunoperoxidase method with a monoclonal antibody
raised against Ki67 (Novocastra, Newcastle, UK). The
cell nuclei were identified as positive or negative and
counted. At least 1200 hepatocytes and 600 bile duct
epithelial cells were analyzed in three independent fields.
Endothelial cell proliferation was assessed by counting
the percentage of Ki67 positive endothelial cell nuclei in
the periportal vessels of five independent high-magnifi-
cation (3400) fields per animal. The vascular density in
the periportal fibrosis was assessed by determining the
count of vWF-labeled vessel sections in 10 successive
high-magnification (3400) fields per animal using an eye-
piece with a net micrometer (Carl Zeiss, Jena, Germany).
The liver samples of at least two rats at each time point
(normal rats, 1, 3, and 6 weeks after BDL) were exam-
ined. The same procedure was applied to determine the
count of bile duct sections. For endothelial cell prolifera-
tion and vascular density data, mean values for more
than two groups (at each time point) were compared by
analysis of variance (Kruskall-Wallis test) and in case of
significance, Scheffé or Games-Howell tests were used
to detect difference between single groups. All results
were expressed as mean 6 SEM.
Reverse Transcription Polymerase Chain
Reaction Analysis of VEGF Transcripts
Total RNAs were extracted by a guanidinium thiocyanate
based method using a commercial kit (Trizol, Gibco
BRL). Five micrograms of RNAs were reverse transcribed
using a commercial kit (Pharmacia Biotech). Samples of
cDNA were subjected to VEGF amplification combined
with GAPDH co-amplification by polymerase chain reac-
tion (PCR). The VEGF and GAPDH oligonucleotide prim-
ers were designed based on published rat cDNA se-
quences in EMBL database. The VEGF sense primer was
59-ACCTCCACCATGCCAAGT-39 (position on cDNA: 54–
71) and the antisense primer was 59-TAGTTCCCGAAAC-
CCTGA-39 (position on cDNA: 602–619). The GAPDH
sense primer was 59-CCATGGAGAAGGCTGGGG-39
(position on cDNA: 335–352) and the antisense primer,
59-CAAAGTTGTCATGGATGACC-39 (position on cDNA:
510–529). PCR was performed in a 50-ml reaction mixture
containing: 10 mmol/L Tris-HCl, pH 9.0); 50 mmol/L KCl;
1.5 mmol/L MgCl2; 0.2 mmol/L dNTPs; 25 pmol/L of each
VEGF primer; and 2.5 pmol/L of each GAPDH primer. The
PCR conditions were as follow: 94°C for 7 minutes, then
25, 28, 31, 34, and 37 cycles of 1 minute denaturation at
94°C, 1 minute annealing at 57°C, 1 minute 30 seconds
extension at 72°C, and a 10-minute terminal extension at
72°C. To monitor the kinetics of PCR product formation,
aliquots were withdrawn at different PCR cycles and an-
alyzed by Southern blot after hybridization of the mem-
brane with specific VEGF and GAPDH 32P-labeled
probes. PCR products were semiquantified by optical
density scanning of the blot.
Western Blot Analysis of FGF-2 Expression
Tissue samples were homogenized using an all-glass
homogenizer in ice-cold lysis buffer (Tris 20 mmol/L, pH
7.5; NaCl, 150 mmol/L; SDS, 2%; EDTA, 5 mmol/L; apro-
tinin, 5 mg/ml; leupeptin, 1 mg/ml; pepstatin, 0.7 mg/ml;
N-tosyl-L-lysine chloromethylketone, 50 mg/ml; N-tosyl-L-
phenylalanine chloromethylketone, 100 mg/ml; soybean
trypsin inhibitor, 100 mg/ml; phenylmethylsulfonyl fluo-
ride, 1 mmol/L) and then sonicated. The cellular debris
were pelleted by two 20-minute centrifugations (15,000 3
g) at 4°C. The protein concentration was determined by
the BCA protein assay (Pierce, Rockford, IL) and aliquots
were stored at 280°C. Equal amounts of proteins were
heated at 95°C for 4 minutes in SDS, dithiothreitol, and
b-mercaptoethanol containing sample buffer and frac-
tionated by 12% SDS-PAGE. After transfer onto a nitro-
cellulose membrane, FGF-2 was detected by using a
rabbit anti-FGF-2 polyclonal antibody (Santa Cruz Bio-
technology) at a dilution of 1:500. Immune complexes
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were revealed by means of a horseradish peroxidase-
conjugated anti-rabbit IgG antibody and an enhanced
chemiluminescence kit (Amersham).
Hypoxia Assay
Pimonidazole binding has been used to assess changes
in hepatic tissue oxygenation.15 Nitroimidazole com-
pounds such as pimonidazole are reductively activated
and covalently bound to macromolecules in cells at low
oxygen concentration.16 In brief, the rats were injected
with pimonidazole (120 mg/ml intravenously) 1 hour be-
fore killing at 1 week, 2 weeks, and 4 weeks following bile
duct ligation or sham operation. Liver tissue was formalin-
fixed and embedded in paraffin. Pimonidazole adducts
were detected in formalin-fixed paraffin-embedded tis-
sues with a biotin-streptavidin-peroxidase indirect immu-
nostaining method modified for rat liver as previously
described, using a monoclonal antibody provided by
J. A. Raleigh.16
Results
Vascular Proliferation Associated with
Cholestatic Liver Injury
Bile duct ligation triggered major structural changes in
the liver architecture, as previously described.3,17 After 3
days, ductular reaction was readily detectable, and after
3 weeks, the ductular reaction was intense and associ-
ated with extensive fibrosis. After 7 weeks, biliary cirrho-
sis was present. Increased cell proliferation in response
to cholestatic liver injury occurred in both parenchymal
and nonparenchymal liver cells, as established before.
The kinetics of cell proliferation as ascertained by Ki67
immunolabeling varied according to cell types: bile duct
epithelial cells were the first to proliferate and reached a
plateau at 3 days, whereas the proliferation of hepato-
cytes peaked at 1 week. The rate of positive nuclei in bile
ducts raised from 1.5% in normal liver to 38% at 3 days,
while that of hepatocytes raised from 1.5% in normal liver
to 18% at 1 week. Proliferation of the vascular endothelial
cells lining periportal vessels was determined on the
same liver sections by the number of Ki67-positive nuclei
in these cells. While no significant change was noted up
to 1 week, inasmuch as 1.79 6 1.79%, 6.25 6 2.19% (ns)
and 13.01 6 2.98% (ns) of nuclei were positive in normal
rats, 3 days and 1 week after bile duct ligation, respec-
tively, an increase in the rate of Ki67-labeled nuclei oc-
curred thereafter and reached 27.86 6 3.59% at 2 weeks
(P , 0.05 as compared with normal, 3 days and 1 week)
(Figure 1, A and B).
After vascular endothelial cells has been identified by
von Willebrand factor immunolabeling, vessel sections
within the ductular reaction were counted to determine
vascular density, as described under Materials and
Methods. In normal rats, vWF was restricted to the endo-
thelium of portal veins (Figure 2A) and central veins (not
shown). One week after BDL, there was no significant
change in vascular density (Figure 2B). In contrast, after
3 weeks and 6 weeks, there was a marked increase in
vWF-labeled vessels that were located within ductular
reaction (Figure 2, C and D). The results are entirely
consistent with the time course of vascular endothelial
cell proliferation as shown in Figure 1. Similarly, the pro-
liferation of bile duct epithelial cells was followed by a
significant increase in bile duct sections at 1 week. The
quantification of vascular density is shown in Figure 2E
(left) in parallel with that of ductular proliferation (Figure
2E, right), that was assessed by the same method. How-
ever, both proliferation events occurred at different time
points.
Hepatic Expression of Angiogenic Factors VEGF
and FGF-2 in Cholestatic Liver Injury
On liver sections from normal rats, VEGF and FGF-2
immunolabeling was detected in the first row of perive-
nular hepatocytes (Figure 3, A and B). In addition, 3% of
hepatocytes unevenly distributed within the lobule dis-
Figure 1. Time course of vascular endothelial cell proliferation after BDL.
Vascular endothelial cell proliferation was assessed by Ki67 immunodetec-
tion on liver tissue sections. A represents the percentage of labeled endo-
thelial cell nuclei in periportal area vessels from normal rats (DO), and 3 days
(D3), 1 week (W1), and 2 weeks (W2) after BDL. While no significant change
was observed up to 1 week, an increase in the rate of Ki67-labeled nuclei
occurred at 2 weeks. All of the results are expressed as means 6 SEM, *P ,
0.05. B illustrates immunodetection of Ki67 in endothelial cells of periportal
vessels at 2 weeks. Positive nuclei are indicated by arrows. Immunoperox-
idase technique with hematoxylin counterstain. Magnification, 31000.
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played FGF-2 reactivity. The labeling intensity was high in
1%, and moderate in 2% of hepatocytes (Figure 3B). No
expression was found in the other cell types. Two weeks
(data not shown) and 3 weeks (Figure 3C) after BDL,
more than 95% of hepatocytes exhibited VEGF immuno-
labeling. Seven weeks after BDL, an intense and homo-
geneous signal for VEGF was observed in 100% of hepa-
tocytes (Figure 3E). VEGF immunolabeling was restricted
to hepatocytes and was undetectable in nonparenchymal
cells, including bile duct epithelial cells and myofibro-
Figure 2. Angiogenesis associated with the development of biliary-type liver fibrosis. Vascular endothelial cells were labeled by an anti-vWF antibody in the liver
of normal rats (A), 1 week (B), 3 weeks (C), and 6 weeks (D) after BDL. The number of vessel sections per field at each time point is presented (E; left panel):
normal (W0); 1 week (W1); 3 weeks (W3), P , 0.0001 as compared with 1 week; and 6 weeks (W6). The number of bile duct sections per field was assessed
by the same method (E; right panel): normal (W0); 1 week (W1), P , 0.05 as compared with normal; 3 weeks (W3), P , 0.0001 as compared with 1 week; and
6 weeks (W6). All of the results are expressed as means 6 SEM (n 5 20); *P , 0.05; **P , 0.0001. Immunoperoxidase technique with hematoxylin counterstain.
Magnification, 3400 (A–D).
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blasts. A similar pattern of VEGF expression was ob-
tained with the two different polyclonal anti-VEGF anti-
bodies that we have used (data not shown). FGF-2
expression also increased after BDL but the time course
and distribution pattern differed from those of VEGF (Fig-
ure 3, D and F). A significant signal for FGF-2 was de-
tected in 49% (intense in 9%) of hepatocytes 3 weeks
after BDL (Figure 3D) and in more than 95% (intense in
35%) of hepatocytes after 7 weeks (Figure 3F).
Since different molecular species of rat VEGF (120,
164, and 188 amino acids) and human VEGF (121, 165,
189, and 206 amino acids) have been identified and
reported to be produced by alternative splicing of
mRNA,18,19 we investigated whether specific isoform
transcripts were induced by cholestatic liver injury. We
characterized the kinetics of expression of these different
transcripts by RT-PCR 2, 4, and 6 weeks after BDL.
Sham-operated rats were used as controls. Three bands
Figure 3. Increased expression of VEGF and FGF-2 after BDL. VEGF (A, C, E) and FGF-2 (B, D, F) were detected by immunohistochemistry. In normal rats (A,
B), the liver architecture was normal and the expression of VEGF and FGF-2 was detected in perivenular hepatocytes. A few scattered hepatocytes (3%) within
the lobule also displayed FGF-2 immunoreactivity (B). Three weeks after BDL (C, D), at the stage of intense ductular reaction and extensive fibrosis, more than
95% of hepatocytes exhibited a signal for VEGF (C), while a signal for FGF-2 was identified in 49% of hepatocytes (intense in 9%, moderate in 40%). At 7 weeks
after BDL (E, F), at the stage of biliary cirrhosis, a signal for VEGF was detected in 100% of hepatocytes, while a signal for FGF-2 was detected in more than 95%
of hepatocytes (intense in 35% of hepatocytes unevenly distributed within the lobule). Immunoperoxidase technique with hematoxylin counterstain. Magnifi-
cation, 3100 (A–D) and 3200 (E, F).
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at 434, 565, and 687 bp were amplified in the different
liver samples. Sequence analysis of these bands showed
that they corresponded to the 120-, 164- and 188-amino-
acid isoforms of VEGF, respectively. The band at 687 bp
corresponding to the 188-amino-acid isoform was the
predominant form in the sham-operated animals and re-
mained unchanged after BDL (Figure 4, A and B). In
contrast, the bands at 434 and 565 bp, corresponding to
the 120- and 164-amino-acid isoforms respectively, in-
creased by 1.5 to 2-fold 4 weeks after BDL. Moreover, the
transcript of 164-amino acid isoform became predomi-
nant within 2 weeks after BDL (Figure 4, A and B).
Unlike VEGF isoforms, the different molecular forms of
FGF-2 represent alternative translation products derived
from a single mRNA20,21 and were therefore analyzed by
immunoblot. Consistent with immunohistochemistry,
Western blot analysis showed that up-regulation of FGF-2
expression was evident after the fourth week following
BDL and increased progressively up to week 7 (Figure 5).
Three isoforms of 18, 21, and 22 kd were detected (Fig-
ure 5). The former corresponds to an AUG codon initiated
form while the 21- and 22-kd peptides are initiated at
codons CUG3 and CUG2, respectively.21 The 22-kd
FGF-2 was the main isoform expressed in all samples
and the 31-kd FGF-2 initiated at CUG1 codon22 was
undetectable even after long time exposures.
We concluded from these data that cholestatic liver
injury induces within 2 weeks a shift in VEGF isoform
transcripts associated with an increase in VEGF immu-
noreactivity in hepatocytes and a delayed increase in
FGF-2 expression, also mainly in hepatocytes.
Induction of Liver Hypoxia
The demonstration of an intense hepatocellular overex-
pression of VEGF following BDL prompted us to investi-
gate the role of liver hypoxia as a triggering event. In
normal rats (Figure 6A, top) pimonidazole adducts were
undetectable in the liver. One week after BDL, a patchy
staining for pimonidazole adducts was observed (data
not shown). Two weeks and 4 weeks after surgery (Figure
6, B and C, respectively; top), pimonidazole adducts
were detected in more than 95% of hepatocytes. In nor-
mal rats (Figure 6A, bottom) and at 1 week (data not
shown), VEGF was detected in perivenular hepatocytes.
Pimonidazole adducts and VEGF expression displayed
the same pattern on adjacent liver sections 2 weeks
(Figure 6B, bottom) as well as 4 weeks after BDL (Figure
6C, bottom). Determination of PO2 in the peripheral arte-
rial blood from the same animals revealed no significant
change in the oxygen tension of rats 3 weeks, 4 weeks as
well as 6 weeks after BDL, as compared with normal rats.
We conclude from these data indicate that hypoxia
selectively occurs in hepatocytes and immediately pre-
cedes the induction of VEGF in these cells after BDL.
Figure 4. BDL-induced expression of VEGF transcripts. Whole liver RNA
extracts were prepared from normal rats (control) rats and 2 weeks, 4 weeks,
and 6 weeks after BDL. Total RNAs (5 mg) were subjected to RT-PCR for
VEGF and GAPDH as described under Materials and Methods. Aliquots were
withdrawn from the PCR mixture after the indicated numbers of cycles (25,
28, 31, 34, and 37) and analyzed by Southern blotting. The signal intensities
of bands corresponding to the 120-, 164-, and 188-amino acid VEGF isoforms
and to GAPDH were determined by scanning densitometry. A: representative
autoradiograms obtained from a control animal and 4 weeks after BDL. B:
Relative abundance of the three transcripts was determined after 31 PCR
cycles in control and BDL rats at 2, 4, and 6 weeks (results are expressed as
means 6 SEM, n 5 3).
Figure 5. BDL-induced expression of FGF-2 isoforms. Total proteins from
whole liver were subjected to Western blot analysis as described under
Materials and Methods. The time after BDL is indicated at the top of the lanes.
The control consists of total proteins extracted from a normal rat liver. The
bands corresponding to the 18-kd (AUG), 21-kd (CUG3), and 22-kd (CUG2)
isoforms are indicated. FGF-2 isoforms were quantified by scanning densi-
tometry and the total amount of the different isoforms are represented on the
histogram at the bottom of the figure.
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Discussion
Our study provides first evidence for the induction of
angiogenic factors VEGF and FGF-2 leading to vascular
proliferation during experimental liver fibrogenesis. In ad-
dition, we demonstrate that hypoxia occurs in hepato-
cytes before the onset of cirrhosis and immediately pre-
cedes VEGF induction. Our results therefore suggest that
hypoxia-induced expression of VEGF in hepatocytes
might be the triggering event in the development of mi-
crovascular proliferation associated with liver fibrogen-
esis and might thereby contribute to the remodeling of
liver architecture .
It has been established that sinusoidal perfusion is
impaired in cirrhosis, whatever its cause12,13 and regen-
erative nodules in human and experimental cirrhosis are
constantly surrounded by a dense perinodular vascular
plexus.1–3 These numerous and tortuous microvessels
originate from intrahepatic vascular branches, progress
together with the fibrous repair process and bypass the
obstructed normal route.1 These observations suggest
that an impaired oxygen delivery to the hepatocytes may
occur in cirrhosis as a result of intrahepatic shunts or
capillarization of the sinusoids, leading to hepatocyte
hypoxia.23 In agreement with this view, we identified an-
giogenesis and hypoxia in cirrhotic tissues. However, our
data indicate that hypoxia, VEGF induction, and angio-
genesis precede the onset of cirrhotic lesions. Early hyp-
oxia is compatible with the occurrence of liver blood
supply impairment long before cirrhosis13.
The immunochemistry data showed an early induction
of VEGF in hepatocytes. Furthermore, this VEGF expres-
sion paralleled an increase in the level of transcripts
coding for the secreted isoforms VEGF120 and VEGF164
which act directly on the proliferation and migration of
vascular endothelial cells. These isoforms also increase
the permeability of microvessels to circulating macromol-
ecules.19 In contrast to VEGF121 and VEGF165, human
VEGF189 binds to the extracellular matrix and requires
hydrolysis by proteases like plasmin to be activated.24 Of
note, plasma urokinase-type plasminogen activator in-
creases in liver cirrhosis25 and myofibroblastic hepatic
stellate cells synthesize components of the plasminogen-
activating system, generating plasmin that plays a key
role in matrix remodeling.26 In addition, VEGF has other
biological activities (such as induction of the expression
of different proteases by endothelial cells27,28 and stim-
ulation of endothelial cells and monocyte procoagulant
activity29) that might also indirectly induce microvascular
remodeling in the liver by promoting monocyte migration
and adhesion of activated neutrophil.13,29 The time
course of vessel proliferation after BDL was entirely con-
sistent with an angiogenic response to VEGF induction.
By immunochemistry, we also found an up-regulation
of FGF-2 was delayed by comparison with VEGF expres-
sion after BDL. Western blot analysis indicated that the
22-kd FGF-2 was the main isoform expressed in this
experimental model. FGF-2 acts as a potent mitogen and
an inducer of cell migration in different cell types, includ-
ing endothelial cells and fibroblasts.30 Low and high mo-
lecular weight isoforms of human FGF-2 generated by
alternative initiation of translation have been de-
scribed.21,31 It has been suggested that the low molec-
ular weight form (18 kd) might modulate cell motility and
proliferation through interaction with its cell surface re-
ceptor while the high molecular weight isoforms (22 to 24
kd) might only act as a mitogen through an intracellular
mechanism.20 FGF-2 expression has been shown to be
associated with fibrous septa in both human and exper-
Figure 6. BDL-induced hypoxia of the liver. Top: In normal rats (A) pimonidazole adducts were not detected in the liver. Two weeks (B) and 4 weeks (C) after
surgery, pimonidazole adducts were detected in more than 95% of hepatocytes. Bottom: In normal rats (A), VEGF was detected in perivenular hepatocytes. Two
weeks (B) and 4 weeks (C) after BDL, VEGF expression displayed the same pattern as pimonidazole adducts on adjacent liver sections. Immunoperoxidase
technique with hematoxylin counterstain. Magnification, 3100 (A) and 3200 (B, C).
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imental chronic liver diseases.32 In addition, a synergism
between FGF-2 and VEGF in the induction of angiogen-
esis and activated hepatic stellate cell proliferation has
been demonstrated33. Finally, FGF-2 has been shown to
inhibit endothelial cell apoptosis.34 Altogether, these data
suggest that FGF-2 might contribute to maintain a vas-
cular proliferative reaction previously induced by VEGF.
Our results strongly argue for the role of hepatocyte
hypoxia as an early triggering event in the induction of
VEGF in this experimental model. It has been previously
demonstrated that hypoxia induces VEGF at both mRNA
and protein level.35,36 Furthermore, hypoxia-induced up-
regulation of VEGF expression has been shown to involve
both a transcriptional activation37 and a stabilization of
transcripts.38 However, we cannot definitively exclude an
additional role of factors produced by activated inflam-
matory cells,39,40 since certain cytokines or growth fac-
tors (ie, EGF, HGF, PDGF, TGF-b) are able to stimulate
VEGF expression in specific cell types.41–44 Neverthe-
less, infiltration by inflammatory cells remained moderate
in our experiments. In addition, the induction of VEGF in
hepatocytes was associated with the concomitant occur-
rence of hypoxia in the same areas. In contrast, the
expression of FGF-2, which has been shown to be insen-
sitive to hypoxia,43,45 was induced later and did not re-
spond to the same distribution pattern suggesting that
the inducing factors involved in the expression of the two
angiogenic factors are different.
In conclusion, our results demonstrate for the first time
the sequential induction of two major angiogenic factors,
VEGF and FGF-2, during biliary-type liver fibrogenesis.
They suggest that hypoxia might be a major factor impli-
cated in the induction of VEGF and in the marked angio-
genesis occurring at an early stage before the onset of
cirrhotic lesions. Further studies are now required to de-
termine the importance of these factors in liver diseases
and whether their modulation might influence the pro-
gression of liver tissue repair.
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